Companies / Congruence Therapeutics
Computationally driven drug discovery using its Revenir platform (biophysics and machine learning) to design small-molecule correctors for protein-misfolding diseases.
congruencetx.com| Round | Date | Amount | Investors |
|---|---|---|---|
| Undisclosed | Mar 19, 2026 | US$39.5M | Dimension and OrbiMed (co-leads); Amplitude Ventures, Fonds de solidarité FTQ, Lumira Ventures, Investissement Québec, BDC Thrive Venture Fund, Driehaus Capital Management, Silver Arc Capital. Co-led by Dimension (new) and OrbiMed; Amplitude Ventures, FSTQ, Lumira, Investissement Québec, BDC Thrive Venture Fund, Driehaus and Silver Arc participated |
| Undisclosed | Sep 4, 2025 | US$32M | Amplitude Ventures, Fonds de solidarité FTQ, Lumira Ventures, Investissement Québec, BDC Thrive Venture Fund, OrbiMed, Driehaus Capital Management, Silver Arc Capital, Alexandria Venture Investments. Insider round from existing investors (Amplitude Ventures, Fonds de solidarité FTQ, Lumira Ventures, Investissement Québec, BDC Thrive Venture Fund, OrbiMed, Driehaus, Silver Arc, Alexandria) to fund the CGX-926 Phase 1. Announcement date per BioWorld Sep 5 2025 coverage, to confirm |
Data as of September 26, 2026. Suggest a correction